Annovis Bio, Inc. (NYSE: ANVS)
Health Care · Biotechnology · US
$0.99
-17.90% today · -52.0% 1Y
Annovis Bio, Inc. (NYSE: ANVS) operates in the Biotechnology industry within the Health Care sector. The company is valued at $42.32M and employs 7 people.
Over the last twelve months the share price has lost 52.0%, trading between 0.99 and 5.50.
Tweenvest scores Annovis Bio, Inc. across four factors: quality 29/100, value 14/100. Its strongest factor is quality.
ANVS price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $42.32M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -1.79
- Dividend yield
- —
- Beta (5Y)
- 1.23
- 52-week high
- $5.50
- 52-week low
- $0.99
- Avg volume (3M)
- —
- Shares outstanding
- 42.61M
- Employees
- 7
- Next earnings
- —
About Annovis Bio, Inc.
Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for neurodegenerative disorders. The firm's flagship drug, Buntanetap, an oral medication, has successfully advanced through Phase 2a clinical trials for Alzheimer's and Parkinson's diseases. This compound is also currently being evaluated in clinical studies for Alzheimer's disease in individuals with Down Syndrome, as well as for various other chronic neurodegenerative conditions. Beyond Buntanetap, Annovis Bio is developing ANVS405 to offer protection against traumatic brain injury and stroke. Additionally, ANVS301 is progressing through Phase I clinical trials, aiming to enhance cognitive capabilities in the later stages of Alzheimer's disease and broader dementia. The company was founded in 2008 and operates out of Berwyn, Pennsylvania.
- ISIN
- US03615A1088
- Founded
- 2008
- Listed since
- Jan 29, 2020
- Exchange
- New York Stock Exchange
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Biomea Fusion, Inc.NasdaqGS: BMEA | $43.50M | $0.60 | +2.58% |
| CapForce Inc.OTCPK: CFOR | $43.39M | $3.50 | -12.37% |
| ABION Inc.KOSDAQ: A203400 | $43.09M | ₩— | — |
| Psomagen, Inc.KOSDAQ: A950200 | $42.85M | ₩2,970.00 | -0.17% |
| Aldeyra Therapeutics, Inc.NasdaqCM: ALDX | $42.23M | $0.70 | -23.59% |
| Dogwood Therapeutics, Inc.NasdaqCM: DWTX | $41.47M | $1.22 | -12.86% |
| Biomolecular Life Holdings, Inc.OTCPK: BIOM | $41.44M | $0.81 | -18.18% |
| KoBioLabs, IncKOSDAQ: A348150 | $40.93M | ₩2,810.00 | -2.43% |
Figures last refreshed Oct 18, 2026.